Details of the Potential Loan

U.S. Government formalizes interest to provide a loan to launch Kodak Pharmaceuticals in the amount of $765M.

The loan application is currently on hold. If finalized, the company would produce generic pharmaceutical components, strengthening U.S. supply chains and creating American jobs.

Why it Matters?

The US consumes 40% of the world’s active pharmaceutical ingredients (APIs), but the majority of these APIs come from India and China.

Kodak Pharmaceuticals would have the ability to produce up to 25% of US pharmaceutical components for generic usage*.

*APIs are used to produce generic pharmaceuticals. Kodak Pharmaceuticals would produce APIs for generic usage that are neither antibacterial nor biologics.

The deal would stimulate the Rochester, NY economy with 300 direct and 1,200 indirect jobs.

Why Kodak?

- 100+ years of experience in advanced materials, chemicals, and chemical manufacturing, with existing team of scientists, chemists, engineers, technicians, and commercialization managers.
- Capacity to make up to 30 different APIs to be used in formulating generic drugs.
- Ability to immediately store and stockpile “Key Starting Materials” (KSM) for the current pandemic and future health crisis situations, as well as produce unregulated KSMs for Essential Medicines in Shortage utilizing existing facilities.
- Primary location at Rochester, NY’s Eastman Business Park, an existing 1,200 acre industrial site with the infrastructure to support these manufacturing needs.